Pediatrix Medical Group, Inc. — Q3 2022 Form 10-Q
Business context and period. The filing covers the quarter and nine months ended September 30, 2022. Pediatrix provides physician services focused on women, newborns and children across 37 states and Puerto Rico. On July 1, the company changed its name from Mednax, Inc.; its NYSE ticker remained MD.
Financial performance
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $489.9 million | $492.9 million | $1,458.2 million | $1,412.7 million |
| Operating income | $47.4 million | $58.8 million | $136.7 million | $134.9 million |
| Operating margin | 9.7% | 11.9% | 9.4% | 9.6% |
| Income from continuing operations | $28.8 million | $31.8 million | $38.6 million | $67.7 million |
| Net income attributable to Pediatrix | $30.7 million | $30.8 million | $36.7 million | $83.4 million |
| Diluted EPS from continuing operations | $0.35 | $0.37 | $0.45 | $0.79 |
| Adjusted EBITDA from continuing operations | $58.3 million | $73.4 million | $174.5 million | $184.4 million |
Revenue and costs. Q3 revenue decreased 0.6%; same-unit revenue fell 3.2%, as a 3.5% decline in reimbursement-related factors more than offset 0.3% volume growth. For the nine months, revenue rose 3.2%, driven primarily by acquisitions, while same-unit revenue declined 1.6%. Management cited revenue-cycle transition effects and a higher share of patients in government-sponsored programs, which generally reimburse less than commercial payors. Q3 practice salaries and benefits rose 4.3%, and supplies and other operating expenses rose 22.0%; lower G&A and restructuring costs partly offset these increases.
Cash flow and liquidity. Continuing-operations operating cash flow was $80.0 million for the first nine months, versus $38.7 million a year earlier; total operating cash flow, including discontinued operations, was $68.3 million. Continuing-operations investing cash use was $45.7 million, including $28.2 million for acquisitions and $20.7 million in capital expenditures. Cash and cash equivalents were $8.7 million at September 30, down from $387.4 million at year-end; short-term investments were $91.4 million. Working capital was $72.0 million, down from $413.2 million, primarily reflecting the debt refinancing and redemption.
Debt. Pediatrix redeemed its $1.0 billion 2027 Notes in February and issued $400 million of 5.375% senior notes due 2030. At quarter-end, debt principal included $400 million of 2030 Notes, $243.8 million under the Term A Loan and $95 million drawn on the revolving line; $355 million remained available under the amended credit agreement. The company reported a $57.0 million loss on early extinguishment of debt for the nine-month period. Management said it was in material compliance with debt covenants and expected to remain compliant through 2022.
Material changes, outlook and risks
- Q3 operating income and Adjusted EBITDA declined, with management attributing the pressure to lower same-unit revenue and higher operating expenses. Nine-month GAAP income was also affected by the debt-extinguishment loss and lower discontinued-operations results; 2021 included a $7.3 million building-sale gain and a $9.5 million discrete tax benefit.
- The company acquired two pediatric practices for total consideration of $31.3 million, including contingent consideration, expanding pediatric primary, urgent and specialty care.
- Management expects cash from operations, cash on hand and available credit to fund working capital, anticipated acquisitions and capital expenditures, restructuring costs, repurchases and obligations for at least the next 12 months. No specific revenue or earnings guidance is provided.
- CARES Act relief recognized in continuing operations was $11.4 million in the first nine months of 2022, versus $7.7 million in 2021. Management reported no material COVID-19 impact through the period but said future effects remain uncertain.
- Risks include lower reimbursement or shifts toward government payors, the No Surprises Act and evolving independent dispute resolution rules, healthcare policy and Medicaid changes, and medical-malpractice claims and government audits. Professional-liability exposure was $294.7 million, partly self-insured; a related $50.4 million insurance receivable was recorded.
- A 1% change in interest rates would affect annual pretax income by approximately $3.4 million based on the outstanding variable-rate credit-agreement balance. The filing reported effective disclosure controls and no material change in internal control over financial reporting.
Investor verification priorities
- Track same-unit reimbursement trends, patient volumes, payor mix and revenue-cycle transition effects, particularly against the acquisition-driven revenue growth.
- Review operating-cost trends and the reconciliation of Adjusted EBITDA and Adjusted EPS to GAAP results, including restructuring and other adjustments.
- Confirm liquidity and debt levels, revolver availability, covenant compliance and sensitivity to variable interest rates; reconcile debt principal with balance-sheet carrying amounts.
- Assess the financial effects of the No Surprises Act, potential reimbursement changes and the adequacy of professional-liability reserves and insurance.
- Separate continuing operations from discontinued operations and account for prior-period building-sale and discrete tax items when comparing earnings.